Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Piper Sandler Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $77

Author: Benzinga Newsdesk | November 04, 2025 11:33am
Piper Sandler analyst Allison Bratzel maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price target from $70 to $77.

Posted In: IONS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist